Benchmarking of mutation diagnostics in clinical lung cancer specimens.

Benchmarking of mutation diagnostics in clinical lung cancer specimens.

Treatment of EGFR-mutant non-small cell lung cancer patients with the tyrosine kinase inhibitors erlotinib or gefitinib results in high response rates and prolonged progression-free survival. Despite the development of sensitive mutation detection approaches, a thorough validation of these in a clin...

Full description

Bibliographic Details
Main Authors: Silvia Querings, Janine Altmüller, Sascha Ansén, Thomas Zander, Danila Seidel, Franziska Gabler, Martin Peifer, Eva Markert, Kathryn Stemshorn, Bernd Timmermann, Beate Saal, Stefan Klose, Karen Ernestus, Matthias Scheffler, Walburga Engel-Riedel, Erich Stoelben, Elisabeth Brambilla, Jürgen Wolf, Peter Nürnberg, Roman K Thomas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-05-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3088700?pdf=render

Internet

http://europepmc.org/articles/PMC3088700?pdf=render

Similar Items